BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

...antibody company later acquired by OHF Group; RedCell Inc., which later became ConjuChem Inc.; and DrugAbuse Sciences Inc....
BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

...diseases, Alzheimer's disease (AD) and cancer Not available Oct 2005 - $4.5M IPO on Alternext DrugAbuse Sciences Inc....
BioCentury | Mar 24, 2008
Finance

Nomura's investments

...Celldex (A) Developing vaccines leveraging bacterial vector delivery technologies 1999 $11M PIPE, 1999 Institutional investors DrugAbuse...
BioCentury | Feb 5, 2007
Strategy

Widening the PDE-10 landscape

...better part of 2008, Kastler said. elbion acquired its lead product, Naltrexone Depot , from DrugAbuse...
...to enter Phase III trials for alcohol addiction by year end (see BioCentury, Jan. 22). DrugAbuse...
...is planning rapid development of Buprenorphine Depot for opioid dependence. The compound, also acquired from DrugAbuse...
BioCentury | Jan 22, 2007
Company News

DrugAbuse, elbion deal

...elbion acquired DrugAbuse Sciences' Naltrexone Depot and Buprenorphine Depot for an undisclosed amount of stock. elbion...
...lead compound. Buprenorphine Depot is a sustained-release buprenorphine in preclinical trials to treat opiate addiction. DrugAbuse Sciences Inc....
BioCentury | Jan 20, 2007
Company News

elbion acquires DrugAbuse compounds

...elbion (Leuven, Belgium) acquired Naltrexone Depot and Buprenorphine Depot from DrugAbuse Sciences (Lyon, France) for an...
BioCentury | Jan 24, 2005
Strategy

Alabama spinout

...Hormone (a-MSH) in Phase Ib testing for various skin conditions. Another existing deal is with DrugAbuse...
...to develop Naltrexone Depot , a long-acting injectable formulation of naltrexone in Phase III testing. DrugAbuse...
BioCentury | May 12, 2003
Finance

Ebb & Flow

...held up well in the face of upbeat Phase III data in alcoholism from competitor DrugAbuse...
BioCentury | May 12, 2003
Product Development

Naltrexone: More than a prayer

...don't take the mu-opiod antagonist every day. To get around that problem, Alkermes Inc. and DrugAbuse Sciences Inc....
...developing similar long-acting injectable formulations. Both contend that the market is large enough for two. DrugAbuse...
...20% and 73%, respectively) than placebo patients (p=0.0001 at 12 months) (see BioCentury, May 5). DrugAbuse...
BioCentury | May 5, 2003
Clinical News

Naltrexone Depot: Phase III

...had 20% and 73% more drink-free days than placebo (p=0.002 and p=0.0001, respectively). In January, DrugAbuse...
...heavily and about 8 times more likely to avoid alcohol altogether compared to placebo patients. DrugAbuse...
...trial of the compound, and expects to submit an NDA for Naltrexone Depot next year. DrugAbuse Sciences Inc....
Items per page:
1 - 10 of 54
BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

...antibody company later acquired by OHF Group; RedCell Inc., which later became ConjuChem Inc.; and DrugAbuse Sciences Inc....
BioCentury | Mar 4, 2013
Finance

EdRIP's exit mantra

...diseases, Alzheimer's disease (AD) and cancer Not available Oct 2005 - $4.5M IPO on Alternext DrugAbuse Sciences Inc....
BioCentury | Mar 24, 2008
Finance

Nomura's investments

...Celldex (A) Developing vaccines leveraging bacterial vector delivery technologies 1999 $11M PIPE, 1999 Institutional investors DrugAbuse...
BioCentury | Feb 5, 2007
Strategy

Widening the PDE-10 landscape

...better part of 2008, Kastler said. elbion acquired its lead product, Naltrexone Depot , from DrugAbuse...
...to enter Phase III trials for alcohol addiction by year end (see BioCentury, Jan. 22). DrugAbuse...
...is planning rapid development of Buprenorphine Depot for opioid dependence. The compound, also acquired from DrugAbuse...
BioCentury | Jan 22, 2007
Company News

DrugAbuse, elbion deal

...elbion acquired DrugAbuse Sciences' Naltrexone Depot and Buprenorphine Depot for an undisclosed amount of stock. elbion...
...lead compound. Buprenorphine Depot is a sustained-release buprenorphine in preclinical trials to treat opiate addiction. DrugAbuse Sciences Inc....
BioCentury | Jan 20, 2007
Company News

elbion acquires DrugAbuse compounds

...elbion (Leuven, Belgium) acquired Naltrexone Depot and Buprenorphine Depot from DrugAbuse Sciences (Lyon, France) for an...
BioCentury | Jan 24, 2005
Strategy

Alabama spinout

...Hormone (a-MSH) in Phase Ib testing for various skin conditions. Another existing deal is with DrugAbuse...
...to develop Naltrexone Depot , a long-acting injectable formulation of naltrexone in Phase III testing. DrugAbuse...
BioCentury | May 12, 2003
Finance

Ebb & Flow

...held up well in the face of upbeat Phase III data in alcoholism from competitor DrugAbuse...
BioCentury | May 12, 2003
Product Development

Naltrexone: More than a prayer

...don't take the mu-opiod antagonist every day. To get around that problem, Alkermes Inc. and DrugAbuse Sciences Inc....
...developing similar long-acting injectable formulations. Both contend that the market is large enough for two. DrugAbuse...
...20% and 73%, respectively) than placebo patients (p=0.0001 at 12 months) (see BioCentury, May 5). DrugAbuse...
BioCentury | May 5, 2003
Clinical News

Naltrexone Depot: Phase III

...had 20% and 73% more drink-free days than placebo (p=0.002 and p=0.0001, respectively). In January, DrugAbuse...
...heavily and about 8 times more likely to avoid alcohol altogether compared to placebo patients. DrugAbuse...
...trial of the compound, and expects to submit an NDA for Naltrexone Depot next year. DrugAbuse Sciences Inc....
Items per page:
1 - 10 of 54